Effects of Tiletamine-xylazine-tramadol Combination and its Specific Antagonist on AMPK in the Brain of Rats.
AMPK
brain
tiletamine
tramadol
xylazine
Journal
Journal of veterinary research
ISSN: 2450-7393
Titre abrégé: J Vet Res
Pays: Poland
ID NLM: 101696630
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
24
09
2018
accepted:
09
04
2019
entrez:
6
7
2019
pubmed:
6
7
2019
medline:
6
7
2019
Statut:
epublish
Résumé
Tiletamine-xylazine-tramadol (XFM) has few side effects and can provide good sedation and analgesia. Adenosine 5'-monophosphate-activated protein kinase (AMPK) can attenuate trigeminal neuralgia. The study aimed to investigate the effects of XFM and its specific antagonist on AMPK in different regions of the brain. A model of XFM in the rat was established. A total of 72 Sprague Dawley (SD) rats were randomly divided into three equally sized groups: XFM anaesthesia (M group), antagonist (W group), and XFM with antagonist interactive groups (MW group). Eighteen SD rats were in the control group and were injected intraperitoneally with saline (C group). The rats were sacrificed and the cerebral cortex, cerebellum, hippocampus, thalamus, and brain stem were immediately separated, in order to detect AMPKα mRNA expression by quantitative PCR. XFM was able to increase the mRNA expression of AMPKα1 and AMPKα2 in all brain regions, and the antagonist caused the opposite effect, although the effects of XFM could not be completely reversed in some areas. XFM can influence the expression of AMPK in the central nervous system of the rat, which can provide a reference for the future development of anaesthetics for animals.
Identifiants
pubmed: 31276069
doi: 10.2478/jvetres-2019-0027
pii: jvetres-2019-0027
pmc: PMC6598187
doi:
Types de publication
Journal Article
Langues
eng
Pagination
285-292Déclaration de conflit d'intérêts
Conflict of Interest Conflict of Interests Statement: The authors declare that there is no conflict of interests regarding the publication of this article.
Références
Eur J Biochem. 1999 May;262(1):184-90
pubmed: 10231380
Brain Res. 1999 Dec 4;849(1-2):169-74
pubmed: 10592299
Eur J Pharmacol. 2000 Jan 10;387(2):141-50
pubmed: 10650154
J Mol Neurosci. 2001 Aug;17(1):45-58
pubmed: 11665862
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Eur J Neurosci. 2003 Feb;17(3):455-66
pubmed: 12581164
Br J Anaesth. 1976 May;48(5):463-8
pubmed: 1276019
Eur J Pharmacol. 2004 Apr 26;491(1):1-8
pubmed: 15102527
Neurochem Res. 2007 Apr-May;32(4-5):681-94
pubmed: 17043768
Vet Rec. 2010 Sep 25;167(13):489-92
pubmed: 20871083
Endocr Relat Cancer. 2011 Jan 13;18(1):181-92
pubmed: 21159731
Nat Cell Biol. 2011 Feb;13(2):132-41
pubmed: 21258367
J Vet Sci. 2011 Sep;12(3):281-6
pubmed: 21897102
Neurosci Lett. 2013 Dec 17;557 Pt A:9-18
pubmed: 23831352
Anesth Analg. 2014 Aug;119(2):311-20
pubmed: 25046786
Crit Rev Eukaryot Gene Expr. 2015;25(1):59-75
pubmed: 25955819
J Zoo Wildl Med. 2015 Sep;46(3):482-90
pubmed: 26352951
Neuropsychobiology. 2016;73(2):81-91
pubmed: 27002982
Endocrinology. 2016 Jun;157(6):2545-59
pubmed: 27035650
PLoS One. 2016 Apr 06;11(4):e0153169
pubmed: 27049320
Neurotoxicol Teratol. 2017 Jan - Feb;59:62-67
pubmed: 27916716
Oncotarget. 2017 Mar 7;8(10):16109-16121
pubmed: 28147330
Drug Saf. 1996 Jul;15(1):8-29
pubmed: 8862961
Eur J Pharmacol. 1996 Dec 5;316(2-3):157-64
pubmed: 8982682
J Wildl Dis. 1997 Jan;33(1):165-8
pubmed: 9027708